During the last session, Sarepta Therapeutics Inc (NASDAQ:SRPT)’s traded shares were 7.5 million, with the beta value of the company hitting 0.60. At the end of the trading day, the stock’s price was $20.77, reflecting an intraday loss of -3.66% or -$0.79. The 52-week high for the SRPT share is $173.25, that puts it down -734.14 from that peak though still a striking 11.89% gain since the share price plummeted to a 52-week low of $18.30. The company’s market capitalization is $2.04B, and the average intraday trading volume over the past 10 days was 9.17 million shares, and the average trade volume was 4.74 million shares over the past three months.
Sarepta Therapeutics Inc (SRPT) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.93. SRPT has a Sell rating from 1 analyst(s) out of 17 analysts who have looked at this stock. 6 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 10 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be 1.2.
Sarepta Therapeutics Inc (NASDAQ:SRPT) trade information
Sarepta Therapeutics Inc (SRPT) registered a -3.66% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -3.66% in intraday trading to $20.77, hitting a weekly high. The stock’s 5-day price performance is -45.07%, and it has moved by -45.26% in 30 days. Based on these gigs, the overall price performance for the year is -83.09%. The short interest in Sarepta Therapeutics Inc (NASDAQ:SRPT) is 9.26 million shares and it means that shorts have 1.67 day(s) to cover.
The consensus price target of analysts on Wall Street is $72.5, which implies an increase of 71.35% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $20 and $110 respectively. As a result, SRPT is trading at a discount of -429.61% off the target high and 3.71% off the low.
Sarepta Therapeutics Inc (SRPT) estimates and forecasts
In the rating firms’ projections, revenue will increase 20.54% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 533.16M as predicted by 18 analyst(s). Meanwhile, a consensus of 18 analyst(s) estimates revenue growth to 511.29M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 362.93M and 467.17M respectively. In this case, analysts expect current quarter sales to grow by 46.90% and then jump by 9.44% in the coming quarter.
While earnings are projected to return -250.50% in 2025, the next five years will return 34.45% per annum.
SRPT Dividends
Sarepta Therapeutics Inc is due to release its next quarterly earnings on 2025-May-06. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Sarepta Therapeutics Inc (NASDAQ:SRPT)’s Major holders
Sarepta Therapeutics Inc insiders own 4.44% of total outstanding shares while institutional holders control 93.02%, with the float percentage being 97.35%. BLACKROCK INC. is the largest shareholder of the company, while 626.0 institutions own stock in it. As of 2024-06-30, the company held over 10.32 million shares (or 10.9117% of all shares), a total value of $1.63 billion in shares.
The next largest institutional holding, with 9.04 million shares, is of VANGUARD GROUP INC’s that is approximately 9.5496% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $1.43 billion.
